Stanford study shows drug for treating type-2 diabetes may limit heart disease risk

June 17, 2003

STANFORD, Calif. - A drug used to treat high blood sugar in people with type-2 diabetes also may lower the risk of cardiovascular disease, according to research at Stanford University Medical Center. If larger studies confirm these results, the drug, called rosiglitazone, may be a good choice for patients with type 2-diabetes who require additional medications to prevent heart attacks.

"If you have a diabetes drug that lowers not only blood sugar but also the risk for heart disease, that might be favorable for the patient with diabetes who already takes as many as eight to 12 pills a day," said James W. Chu, MD, director of the Diabetes Center at Santa Clara Valley Medical Center and adjunct clinical investigator at Stanford. Chu and Gerald Reaven, MD, emeritus professor of medicine at the Stanford School of Medicine, will present results from their study June 17 at the annual meeting of the American Diabetes Association in New Orleans.

In type-2 diabetes, the body's tissues are resistant to or don't efficiently respond to insulin's signal to take up sugar from the blood. If the body doesn't overcome this resistance by making extra insulin, blood sugar will rise, leading to diabetes. First described by Reaven, insulin resistance goes hand-in-hand with a group of health problems including obesity, high blood pressure, type-2 diabetes, increased inflammation and heart disease.

To control blood sugar, people with type-2 diabetes take drugs such as rosiglitazone. But as a result of insulin resistance, they are also at risk of heart attacks, requiring additional medications to treat high blood pressure and cholesterol and to prevent arteries from clogging.

Recent studies have suggested that increased inflammation linked to insulin resistance may contribute to an elevated risk of heart disease. "Theoretically, giving a drug that inhibits the inflammatory response might be useful for preventing cardiovascular disease," Reaven said. Based on earlier work showing that rosiglitazone decreases insulin resistance and lowers blood sugar, Chu and Reaven proposed that the drug also may reduce inflammation.

They tested this idea by giving rosiglitazone to 29 people, 14 of whom had type-2 diabetes and 15 who were insulin-resistant but didn't have diabetes. They followed the participants, recording levels of insulin, blood sugar and other blood components that indicate abnormal metabolism or increased risk for heart disease.

After three months of taking rosiglitazone, the study participants had significantly lower levels of certain molecules that indicate the presence of inflammation. Of these molecules, C-reactive protein is a powerful predictor of cardiovascular risk. The other molecules - plasminogen activator inhibitor-1, E-selectin, L-selectin and P-selectin - are often elevated in people with metabolic and cardiovascular disease.

The finding that these inflammatory molecules decreased in patients taking rosiglitazone hints that the drug also may lower the risk of heart disease, but Reaven urges caution in interpreting these results.

"The fact that the phenomenon takes place doesn't mean the end point will change. You still need a much larger study that measures cardiovascular disease in people taking the drug," Reaven said. He also noted that people who are insulin-resistant but do not yet have diabetes should take diabetes medications such as rosiglitazone only as participants in medical research.

Chu said this study could help doctors decide how to distinguish between the five classes of oral diabetes drugs currently available for type-2 diabetes. "Because most people with diabetes die of heart disease, a drug that potentially can treat multiple facets of the insulin-resistance syndrome is exciting," Chu said.
Other Stanford researchers who contributed to the study include Fahim Abbasi, MD, research associate; Cynthia Lamendola, research coordinator; Tracey McLaughlin, MD, clinical instructor; and Philip Tsao, MD, assistant professor of medicine.

Print media contact: Michelle Brandt, 650-723-0272
Broadcast media contact: Neale Mulligan, 650-724-2454

Embargoed for release until: June 17, 2003, at 6 a.m. Pacific time to coincide with a presentation at the annual meeting of the American Diabetes Association

Stanford University Medical Center integrates research, medical education and patient care at its three institutions - Stanford University School of Medicine, Stanford Hospital & Clinics and Lucile Packard Children's Hospital at Stanford. For more information, please visit the Web site of the medical center's Office of Communication & Public Affairs at

Stanford University Medical Center

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to